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‘Equipoise’ is a situation described as a “doubt as towhich of two
clinical interventions is more beneﬁcial for the patient.” In practice,
equipoise mandates that patients may be assigned to different
treatment options as long as there is a professional uncertainty
about which treatment is superior.1 For carotid revascularisation,
uncertainty does not exist while numerous randomised trials have
demonstrated the inferiority of carotid artery stenting (CAS) versus
carotid endarterectomy (CEA) for stroke prevention in symptomatic
patients, especially in patients older than 70 years. Although
asymptomatic patients are still under trial, CAS in asymptomatic
patients has been associated with approximately double the peri-
procedural rate of death/stroke compared with CEA.
The American College of Surgeons stated that it is “essential that
the value and safety of a new procedure is established before it is
widely used on patients.”2 Nowadays, the introduction of new
surgical devices is mostly driven by commercial enterprise, and
most innovative surgical procedures enter practice without regu-
latory oversight.1 The article by Lindstromet al. in fact demonstrates
the potential detrimental impact on patients when a new surgical
procedure is widely introduced at a time of not knowing its safety
and efﬁcacy.3 The authors compared the periprocedural outcome in
a consecutive series of CAS and CEA from a single high-volume
centre (SÖS) with data from low-volume centres derived from the
Swedvasc national database. The authors conclude, “although not as
safe as CEA, a single centre can achieve acceptable resultswith CAS.”
The fact that a single hospital has acceptable outcomes with 208
CAS cases over a 7-year time frame does not convince us that CAS
can be recommended as the ﬁrst line of therapy. Moreover, besides
not supporting the further application of CAS, this analysis far more
indicates what can happen when CAS is applied outside the strict
borders of randomised trials, considering the extraordinary result
within Swedvasc of a 10.9% (11/101) stroke and death rate after CAS
for asymptomatic patients.
The three key messages of this report are:DOI of original article: 10.1016/j.ejvs.2012.01.024.
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doi:10.1016/j.ejvs.2012.02.0071. Observed, acceptable, single-centre results when applying
CAS to a ‘selected’ group of patients deemed ‘high risk’.
However, approximately half of patients in both compared
groups were asymptomatic. It should be clear that asymp-
tomatic patients, by deﬁnition, can never be at high risk for
stroke.
2. Reported and unacceptably high periprocedural death/stroke
rate in asymptomatic patients related to CAS in Swedvasc. If
this article should inﬂuence clinical practice, the death/stroke
rate is astonishingly quite alarming and unacceptable for
elective treatment of carotid stenosis in any patient by any
revascularisation technique.
3. Observed large difﬁculties in comparing single-centre results
with Swedvasc registry data. This maywarrant a revision of the
standardised data gathered in Swedvasc to make future
comparisons more worthwhile and may be an important
lesson for other countries planning to start national registries.
In the past, we have been shown that procedural risk may be
much higher in ‘routine clinical practice’ thanwithin the conﬁnes of
a randomised trial. The present article conﬁrms these observations
and does not add to the safety qualiﬁcation of CAS but far more
should add to the discussion of what happens with broad imple-
mentation of a new technique, especially when applied to
a subgroup of patients that should not receive any type of revas-
cularisation in general. True, depending on certain but still ill-
deﬁned patient characteristics, one procedure might have an
advantage over the other, leaving space for application of CAS in
highly selected cases.4 However, 15% of patients in SÖS were
included for a non-speciﬁed reason, and the indications for
selecting CAS nationally could not be provided at all!
The overall aim of an analysis, such as performed by Lindstrom
et al., should be an internal vascular centre quality control
measure, and every vascular centre should be encouraged to
regularly do so. These measures should include an adequate
feedback mechanism and ideally lead to an adjustment in revas-
cularisation policy, where necessary, to support the ongoing
attempt to make carotid revascularisation a safer process. Ethical
acceptability mandates that the potential beneﬁts of an interven-
tion outweigh any inherent risk of harm. This cannot be the case
with coverage for CAS to routine practice management of
asymptomatic or low-risk patients.ed by Elsevier Ltd. All rights reserved.
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